Search
Suvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalSuvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: BELSOMRA® 15 MG, BELSOMRA® 10 MGVosoritide
go.drugbank.com/drugs/DB11928ApprovedInvestigationalVosoritide is an analog of CNP with proline-glycine on its N-terminus to convey resistance to neutral endopeptidase. … Achondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans.
Categories: C-type Natriuretic Peptide AnalogAntithrombin III human
go.drugbank.com/drugs/DB11598ApprovedInvestigationalA plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Synonyms: Heparin cofactor BProducts: KYBERNIN P, KYBERNIN P 500Voclosporin
go.drugbank.com/drugs/DB11693ApprovedInvestigationalLN is a significant cause of renal failure, morbidity, and death in patients with SLE. … Lupus nephritis (LN) is a type of glomerulonephritis occurring in patients with systemic lupus erythematosus (SLE).
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesPyrethrum extract
go.drugbank.com/drugs/DB11087ApprovedWhile pyrethrum extract is composed of 6 esters, both organic compounds mediate insecticidal activities. … Pyrethrum is the crude extract form obtained from flowers of the plant Chrysanthemum cinerariifolium. Pyrethrin refers to a more refined extract of pyrethrum.
Mixtures: R & C Shampoo With Conditioner, Ki-tapiox Lice TreatmentCategories: Compounds used in a research, industrial, or household settingCrizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigationalCrizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic … [L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement
Synonyms: (R)-crizotinibCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexTaletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigational[L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable … Taletrectinib is an orally available small molecule kinase inhibitor.
Categories: MATE 1 Substrates, MATE 2 InhibitorsMethacholine
go.drugbank.com/drugs/DB06709Approved[A229598, A229603] Although the underlying pathology of AHR is complex, ASM contraction can be stimulated by cholinergic agonists that activate M<sub>3</sub> muscarinic receptors that stimulate ASM contraction … [A229648, L31763] Methacholine was granted FDA approval on October 31, 1986, and is marketed under the trademark PROVOCHOLINE® by Methapharm Inc.[L31763]
Tirzepatide
go.drugbank.com/drugs/DB15171ApprovedInvestigationalTirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. … [A246260] Its protein sequence was based on the sequence of endogenous GIP, and its pharmacological action on GLP-1 receptors is comparable to endogenous GIP; however, the long half-life of tirzepatide
Categories: GLP-1 Agonists, Receptors, G-Protein-CoupledProducts: Mounjaro 5 mg/0,5 ml Enjeksiyonluk Çözelti, 1 ADET, Mounjaro 5 mg/0,5 ml Enjeksiyonluk Çözelti, 4 ADETSiponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigational[L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA … Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS).
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index